Prognostic value of ATRX nucleoprotein deletion in patients with WHO 4 IDH mutant astrocytoma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100053124

Enrollment

Unknown

Registered

2021-11-12

Start date

2022-05-01

Completion date

Unknown

Last updated

2022-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Interventions

ATRX nucleoprotein deletion group:None

Control group:None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with glioma treated by surgical resection and pathological sampling; 2.Willing to provide disease-related data, including pathological diagnosis, relevant documents, medical records, abandoned specimens removed by surgery, etc.; 3.Glioma patients who are willing to provide long-term contact information and maintain follow-up.

Exclusion criteria

Exclusion criteria: 1.For other reasons, the researchers did not consider patients suitable for clinical trials; 2.Patients participating in other clinical studies.

Design outcomes

Primary

Measure	Time frame
Overal survival;Disease free survival;	—

Countries

China

Contacts

Public ContactCai Jinquan

The Second Affiliated Hospital of Harbin Medical University

caijinquan666777@126.com+86 15124572707

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026